Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Catalyst Pharmaceuticals recently reported past fourth-quarter 2025 revenue of US$152.61 million and full-year 2025 revenue of US$588.99 million, alongside net income of US$52.7 million for the quarter and US$214.33 million for the year. Along with issuing 2026 revenue guidance of US$615 million to US$645 million, the company is also engaging investors by presenting at the BIO Investment & Growth Summit in Miami Beach, highlighting growing interest in its rare disease portfolio. With Catalyst now forecasting 2026 revenue of up to US$645 million, we'll examine how this updated outlook reshapes its investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Catalyst Pharmaceuticals Investment Narrative Recap To own Catalyst
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific ConferenceGlobeNewswire
- Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]Yahoo! Finance
CPRX
Earnings
- 2/25/26 - Beat
CPRX
Sec Filings
- 2/25/26 - Form 8-K
- 2/25/26 - Form 10-K
- 2/19/26 - Form 4
- CPRX's page on the SEC website